Rubius Therapeutics (NASDAQ:RUBY) issued its earnings results on Thursday, March 28th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.07, MarketWatch Earnings reports.
Shares of RUBY traded down $0.70 during trading hours on Friday, hitting $17.04. The stock had a trading volume of 153,239 shares, compared to its average volume of 263,301. The company has a current ratio of 20.72, a quick ratio of 20.72 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.36 billion and a P/E ratio of -7.51. Rubius Therapeutics has a 12-month low of $12.70 and a 12-month high of $33.01.
Separately, Zacks Investment Research lowered Rubius Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Rubius Therapeutics has an average rating of “Buy” and an average price target of $30.00.
A number of large investors have recently added to or reduced their stakes in RUBY. BlackRock Inc. purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $38,155,000. New York State Common Retirement Fund purchased a new stake in shares of Rubius Therapeutics during the fourth quarter worth about $116,000. Marshall Wace North America L.P. purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $1,405,000. Teachers Advisors LLC purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $563,000. Finally, Baillie Gifford & Co. purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $93,831,000. 87.07% of the stock is currently owned by institutional investors.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Further Reading: Growth and Income Funds
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.